Screener
ADMA Biologics ADMA Intangibles (Net)
Intangibles (Net) at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:IntangibleAssetsNetExcludingGoodwill.
The source filing: ADMA Biologics’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 5:16 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001140361-26-031445
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Assets held for sale | - | 6,530 |
| Total current assets | 528,203 | 466,512 |
| Property and equipment, net | 66,664 | 65,057 |
| Intangible assets, net | 575 | 632 |
| Goodwill | 3,530 | 3,530 |
| Deferred tax assets, net | 69,965 | 73,261 |
| Right-of-use assets | 6,146 | 6,650 |
| Deposits and other assets | 9,127 | 8,600 |
Item 1. Financial Statements.
FAQ
- What is ADMA Biologics's intangibles (net)?
- ADMA Biologics (ADMA) reported intangibles (net) of $575K in Q2 2026.
- How has ADMA Biologics's intangibles (net) changed year-over-year?
- ADMA Biologics's intangibles (net) increased by 9.1% year-over-year, from $527K to $575K.
- What is the long-term trend for ADMA Biologics's intangibles (net)?
- Over 5 years (2020 to 2025), ADMA Biologics's intangibles (net) has grown at a -23.7% compound annual growth rate (CAGR), from $2.44M to $632K.
- What does intangibles (net) mean?
- Identifiable intangible assets (patents, trademarks, customer relationships, technology) net of accumulated amortization — excluding goodwill.
Ask your AI about ADMA Biologics's intangibles (net).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude